Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension
Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension
Ho et al., 2009 | Cochrane Database Syst Rev | Meta Analysis
Citation
Ho Meghan J, Bellusci Anthony, Wright James M. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev. 2009-Oct-07(4):CD007435. doi:10.1002/14651858.CD007435.pub2
Abstract
BACKGROUND: Studies have shown that coenzyme Q10 deficiency is associated with cardiovascular disease. Hypertension is a commonly measured surrogate marker for non-fatal and fatal cardiovascular endpoints such as heart attacks and strokes. Clinical trials have suggested that coenzyme Q10 supplementation can effectively lower blood pressure (BP). OBJECTIVES: To determine the blood pressure lowering effect of coenzyme Q10 in primary hypertension. SEARCH STRATEGY: The Cochrane Central Register of Controlled Trials (2009 Issue 2), MEDLINE (1966 -May 2008), EMBASE (1982 - May 2008), and CINAHL (1970 - May 2008) as well as the reference lists of articles were searched for relevant clinical trials in any language. SELECTION CRITERIA: Double-blind, randomized, placebo-controlled parallel or crossover trials evaluating the BP lowering efficacy of coenzyme Q10 for a duration of at least 3 weeks in patients with primary hypertension. DATA COLLECTION AND ANALYSIS: The primary author independently assessed the risk of bias and extracted the data. The second author verified data extraction. MAIN RESULTS: Three clinical trials with a total of 96 participants were evaluated for the effects of coenzyme Q10 on blood pressure compared to placebo. Treatment with coenzyme Q10 in subjects with systolic BP (SBP) > 140 mmHg or diastolic BP (DBP) > 90 mmHg resulted in mean decreases in SBP of 11 mmHg (95% CI 8, 14) and DBP of 7 mmHg (95% CI 5, 8). AUTHORS' CONCLUSIONS: Due to the possible unreliability of some of the included studies, it is uncertain whether or not coenzyme Q10 reduces blood pressure in the long-term management of primary hypertension.
Key Findings
Three clinical trials with a total of 96 participants were evaluated for the effects of coenzyme Q10 on blood pressure compared to placebo. Treatment with coenzyme Q10 in subjects with systolic BP (SBP) > 140 mmHg or diastolic BP (DBP) > 90 mmHg resulted in mean decreases in SBP of 11 mmHg (95% CI 8, 14) and DBP of 7 mmHg (95% CI 5, 8). AUTHORS' CONCLUSIONS: Due to the possible unreliability of some of the included studies, it is uncertain whether or not coenzyme Q10 reduces blood pressure in th
Outcomes Measured
- blood pressure
- systolic blood pressure
- diastolic blood pressure
Population
| Field | Value |
|---|---|
| Population | primary hypertension |
| Sample Size | 96 |
| Age Range | See abstract |
| Condition | hypertension |
MeSH Terms
- Antihypertensive Agents
- Bias
- Blood Pressure
- Humans
- Hypertension
- Randomized Controlled Trials as Topic
- Ubiquinone
Evidence Classification
- Level: Meta Analysis
- Publication Types: Journal Article, Meta-Analysis, Systematic Review
- Vertical: coq10-blood-pressure
Provenance
- PMID: 19821418
- DOI: 10.1002/14651858.CD007435.pub2
- PMCID: Not in PMC
- Verified: 2026-04-09 via PubMed E-utilities API
Source extracted via PubMed E-utilities API on 2026-04-09